40
Participants
Start Date
July 22, 2024
Primary Completion Date
September 12, 2024
Study Completion Date
September 21, 2024
PA9159 Inhalation aerosol, 60 μg one day treatment
single dose of PA9159 (60 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 2 puffs.
PA9159 Inhalation aerosol, 120 μg one day treatment
single dose of PA9159 (120 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 4 puffs.
PA9159 Inhalation aerosol, 240 μg one day treatment
single dose of PA9159 (240 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 8 puffs.
PA9159 Inhalation aerosol, 300 μg one day treatment
single dose of PA9159 (300 μg/inhaler spray) is administered by inhalation through an inhaler via the mouth, with 10 puffs.
PA9159 Inhalation aerosol, 120 μg 7-day treatment
Repeated doses of PA9159 (120 μg/inhaler spray) i is administered by inhalation through an inhaler via the mouth, with 4 puffs, twice a day.
Placebo, the same Inhalation aerosol solution without PA9159 active ingredient
Placebo is delivered via the mouth through an inhaler with the same volume as the corresponding PA9159 dose group
The First Affiliated Hospital of Nanchang University, Nanchang
Lead Sponsor
Anhui Palo Alto Pharmaceuticals, Inc.
INDUSTRY